Sorry, you need to enable JavaScript to visit this website.
Skip to main content


IgA nephropathy (IgAN) has a variable but progressive clinical course, which can negatively impact patients’ quality of life (QoL)1–5

The clinical presentation of IgAN and the risk and rate of progression to end-stage kidney disease (ESKD) is highly variable between patients.1–4

Patients may present with:1–5

High proteinuria icon

High proteinuria

Macrohematuria icon


Renal insufficiency icon

Renal insufficiency

Hypertension icon


Kidney injury icon

Acute kidney injury

Edema icon


Kidney biopsy is essential for confirmation of diagnosis in IgAN and to guide subsequent clinical care decisions2,6

Similarly, the rate at which patients progress through different stages of IgAN to kidney failure can be highly variable7–11

Disease population icon

Up to 53% of patientsprogress to ESKD within 20 years of an IgAN diagnosis7–9*

In a population-based cohort study (N=3622), patients with IgAN were found to have a:10

IgA nephropathy mortality risk icon

53% increased risk of mortality compared to matched controls

IgA nephropathy life expectancy icon

6-year reduction in life expectancy compared to matched controls

Variation in clinical course and outcomes leads to delayed diagnosis in patients presenting with established kidney disease.2,11

Proteinuria is a key marker and driver of disease progression

Find out more

Patients’ health-related QoL is affected at all stages of IgAN2,9

IgA nephropathy early stage icon


Find out more
IgA nephropathy mid stage icon


Find out more
IgA nephropathy late stage icon

Late-stage (ESKD)

Find out more

Patients at all stages of IgAN experience symptoms that lower their QoL

The risk-prediction tool can help identify at-risk patients